MedTrace Logo

Superiority Trial Evaluating Digitalized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatment.

NCT06211257 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 377

Last updated 2026-03-18

No results posted yet for this study

Summary

ePPS-2202 is a study designed to evaluate the benefits of a dematerialised personalised care plan (PCP) compared to standard information/PCP for patients with advanced sarcomas receiving systemic treatment.

Participants will be randomised to an experimental group or a control group. Patients in the experimental group will receive the dematerialised PCP in addition to the standard PCP while patients in the control group will receive the standard PCP alone.

All patients will be followed until the end of second-line treatment, the start of a new line of treatment, or until the 24-month follow-up.

Conditions

  • Sarcoma Metastatic
  • Locally Advanced Soft Tissue Sarcoma

Interventions

OTHER

Dematerialized Personalized Care Plan (ePCP)

Post-treatment support with standard support combined with dematerialized support

Sponsors & Collaborators

  • Canceropôle Nord Ouest

    collaborator OTHER

  • Centre Oscar Lambret

    lead OTHER

Principal Investigators

  • Diane PANNIER, MD · Centre Oscar Lambret

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-29
Primary Completion
2028-07-31
Completion
2030-04-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06211257 on ClinicalTrials.gov